These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection. Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366 [TBL] [Abstract][Full Text] [Related]
23. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Guzman MG; Alvarez M; Halstead SB Arch Virol; 2013 Jul; 158(7):1445-59. PubMed ID: 23471635 [TBL] [Abstract][Full Text] [Related]
24. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Guy B; Chanthavanich P; Gimenez S; Sirivichayakul C; Sabchareon A; Begue S; Yoksan S; Luxemburger C; Lang J Vaccine; 2004 Sep; 22(27-28):3563-74. PubMed ID: 15315835 [TBL] [Abstract][Full Text] [Related]
25. Immunological serotype interactions and their effect on the epidemiological pattern of dengue. Recker M; Blyuss KB; Simmons CP; Hien TT; Wills B; Farrar J; Gupta S Proc Biol Sci; 2009 Jul; 276(1667):2541-8. PubMed ID: 19369266 [TBL] [Abstract][Full Text] [Related]
26. [Dengue fever: from disease to vaccination]. Teyssou R Med Trop (Mars); 2009 Aug; 69(4):333-4. PubMed ID: 19725380 [TBL] [Abstract][Full Text] [Related]
28. Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection. Khandia R; Munjal A; Dhama K; Karthik K; Tiwari R; Malik YS; Singh RK; Chaicumpa W Front Immunol; 2018; 9():597. PubMed ID: 29740424 [TBL] [Abstract][Full Text] [Related]
29. Chaotic desynchronization of multistrain diseases. Schwartz IB; Shaw LB; Cummings DA; Billings L; McCrary M; Burke DS Phys Rev E Stat Nonlin Soft Matter Phys; 2005 Dec; 72(6 Pt 2):066201. PubMed ID: 16486034 [TBL] [Abstract][Full Text] [Related]
30. The expression profile of human peripheral blood mononuclear cell miRNA is altered by antibody-dependent enhancement of infection with dengue virus serotype 3. Jiang L; Sun Q Virol J; 2018 Mar; 15(1):50. PubMed ID: 29566761 [TBL] [Abstract][Full Text] [Related]
31. Implementing a dengue vaccination programme-who, where and how? E Clapham H; A Wills B Trans R Soc Trop Med Hyg; 2018 Aug; 112(8):367-368. PubMed ID: 30016491 [TBL] [Abstract][Full Text] [Related]
32. Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus. Renner M; Flanagan A; Dejnirattisai W; Puttikhunt C; Kasinrerk W; Supasa P; Wongwiwat W; Chawansuntati K; Duangchinda T; Cowper A; Midgley CM; Malasit P; Huiskonen JT; Mongkolsapaya J; Screaton GR; Grimes JM Nat Immunol; 2018 Nov; 19(11):1248-1256. PubMed ID: 30323338 [TBL] [Abstract][Full Text] [Related]
33. Episodes of the epidemiological factors correlated with prevailing viral infections with dengue virus and molecular characterization of serotype-specific dengue virus circulation in eastern India. Rao MRK; Padhy RN; Das MK Infect Genet Evol; 2018 Mar; 58():40-49. PubMed ID: 29247706 [TBL] [Abstract][Full Text] [Related]
34. Structural perspectives of antibody-dependent enhancement of infection of dengue virus. Morrone SR; Lok SM Curr Opin Virol; 2019 Jun; 36():1-8. PubMed ID: 30844538 [TBL] [Abstract][Full Text] [Related]
35. Molecular Simulations Reveal the Role of Antibody Fine Specificity and Viral Maturation State on Antibody-Dependent Enhancement of Infection in Dengue Virus. Ripoll DR; Wallqvist A; Chaudhury S Front Cell Infect Microbiol; 2019; 9():200. PubMed ID: 31275864 [TBL] [Abstract][Full Text] [Related]
36. Replacement of pr gene with Japanese encephalitis virus pr using reverse genetics reduces antibody-dependent enhancement of dengue virus 2 infection. Wang Y; Si L; Luo Y; Guo X; Zhou J; Fang D; Yan H; Zeng G; Jiang L Appl Microbiol Biotechnol; 2015 Nov; 99(22):9685-98. PubMed ID: 26219500 [TBL] [Abstract][Full Text] [Related]
37. Dengue viruses and promising envelope protein domain III-based vaccines. Fahimi H; Mohammadipour M; Haddad Kashani H; Parvini F; Sadeghizadeh M Appl Microbiol Biotechnol; 2018 Apr; 102(7):2977-2996. PubMed ID: 29470620 [TBL] [Abstract][Full Text] [Related]
38. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico. Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647 [TBL] [Abstract][Full Text] [Related]
39. Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever. Watts DM; Porter KR; Putvatana P; Vasquez B; Calampa C; Hayes CG; Halstead SB Lancet; 1999 Oct; 354(9188):1431-4. PubMed ID: 10543670 [TBL] [Abstract][Full Text] [Related]